title: Regulation of transplantation immunity in vivo by monoclonal antibodies recognizing host class II restriction elements. I. Genetics and specificity of anti-Ia immunotherapy in murine skin allograft recipients.
abstract: Antibodies reactive with host class II restriction elements exert profound regulatory effects on the immune response to a variety of antigenic stimuli, including tumor, autoantigens, and alloantigens. In the present studies, monoclonal reagents specific for host I-A and I-E glycoproteins were evaluated for their capacity to modulate transplantation immunity in a murine tail skin allograft system. It was found that treatment of A/J mice with 200 micrograms 10-3.6 hybridoma-derived anti-I-Ak antibody daily for 10 days resulted in an average twofold increase in the survival time of B10.A minor antigen-incompatible allografts. Similar results were achieved by using class I, but not H-2-mismatched, donor tissue. Specificity of antibody activity was demonstrated by the failure of isotype-matched reagents recognizing irrelevant class II or relevant class I H-2 antigens to influence rejection under these conditions. Although antibodies reactive with graft as well as host alloantigens provided the greatest degree of prolongation, interaction with host restriction elements alone was sufficient for the in vivo expression of regulatory activity. As in previous studies, anti-I-A treatment was associated with the development of antigen-specific suppressor T cells that serve to dampen allograft immunity without altering secondary responses to unrelated antigens encountered after the initial treatment interval. These data suggest that anti-Ia immunotherapy may provide a clinically relevant approach toward the specific regulation of transplantation immunity in the appropriate donor-recipient combinations.
authors.forename: L L
authors.initials: LL
authors.lastname: Perry
authors.forename: I R
authors.initials: IR
authors.lastname: Williams
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000918:Antibody Specificity; D001667:Binding, Competitive; D004306:Dose-Response Relationship, Immunologic; D000939:Epitopes / Q000276:immunology; D005260:Female; D006084:Graft Rejection; D006183:H-2 Antigens / Q000235:genetics; D006649:Histocompatibility Antigens / Q000235:genetics / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000145:classification / Q000235:genetics / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D016038:Skin Transplantation; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000939:Epitopes; D006183:H-2 Antigens; C024755:H-2K(K) antigen; D006649:Histocompatibility Antigens; D000949:Histocompatibility Antigens Class II; C024138:I-E-antigen